| 利伐沙班在冠心病二级预防中的应用研究进展 |
| |
| 引用本文： | 代新春,陈冰茹,许晓明,程康,李伟杰. 利伐沙班在冠心病二级预防中的应用研究进展[J]. 中国心血管病研究杂志, 2019, 17(11) |
| |
| 作者姓名： | 代新春 陈冰茹 许晓明 程康 李伟杰 |
| |
| 作者单位： | 空军军医大学,空军93279部队医院,空军93279部队医院,西安市第三医院心血管内科,空军军医大学西京医院心血管内科 |
| |
| 摘 要： | 抗血小板治疗在冠心病的二级预防中无可替代。早期的研究显示[1]，抗血小板基础上联合华法林治疗虽可进一步降低冠心病患者未来心血管事件，但出血的危险却显著增加。与华法林相比，非维生素K拮抗口服抗凝药物利伐沙班应用安全、方便，为冠心病的抗栓策略提供了新的选择，联合非维生素K拮抗口服抗凝药及抗血小板治疗的抗栓治疗成为冠心病二级预防研究的热点，本文基于对利伐沙班作用机制的新认识，同时聚焦小剂量利伐沙班（2.5mg 每日两次）在冠心病治疗领域的最新研究进行综述。
|
| 关 键 词： | 利伐沙班；冠心病；动脉粥样硬化；抗栓治疗 |
| 收稿时间： | 2019-05-26 |
| 修稿时间： | 2019-09-03 |
Research progress of rivaroxaban in secondary prevention of coronary heart disease |
| |
| chen bingru,xu xiaoming,cheng kang and li weijie. Research progress of rivaroxaban in secondary prevention of coronary heart disease[J]. Chinese Journal of Cardiovascular Review, 2019, 17(11) |
| |
| Authors: | chen bingru xu xiaoming cheng kang li weijie |
| |
| Affiliation: | Hospital of PLA Unit 93279,Hospital of PLA Unit 93279,Department of Cardiology,Xi''an Third Hospital,Department of Cardiology, Xijing Hospital, Air Force Medical University |
| |
| Abstract: | Antiplatelet therapy plays an irreplaceable role in secondary prevention of coronary heart disease. Early studies have shown that anti-platelet therapy combined with warfarin can further reduce future cardiovascular events in patients with coronary heart disease, but the risk of bleeding is significantly increased. Compared with warfarin, the non-vitamin K antagonists oral anticoagulant, rivaroxaban, is safe and convenient to use and provides a new choice for secondary prevention of coronary heart disease. Combination of non-vitamin K antagonists oral anticoagulant and antiplatelet therapy is a hotspot in current research. Based on new knowledge about the mechanism of action of rivaroxaban, we focus on low-dose rivaroxaban (2.5mg twice a day) and introduce its latest research progress in the field of coronary heart disease. |
| |
| Keywords: | |
|
| 点击此处可从《中国心血管病研究杂志》浏览原始摘要信息 |
|
点击此处可从《中国心血管病研究杂志》下载全文 |
|
